R21AI159379 (LEE, HYUN-SUNG)Sep 1, 2023 - Aug 31, 2025 NIH NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY Role: Co-Principal Investigator (MPI) |
|
R01DK124395 (REDONDO, MARIA JOSE)Feb 15, 2021 - Jan 31, 2025 NIH Type 1 diabetes genetic risk scores for the diagnosis of diabetes type in children of diverse racial and ethnic background Role: Study Principal Investigator |
|
n/a (Redondo, Maria J)Mar 21, 2020 - Jun 1, 2025 Helmsley Charitable Trust Emergency Funding to Support Underserved T1D Populations Impacted by the COVID-19 Pandemic Role Description: Goal: To implement the use of telemedicine and other clinical initiatives to alleviate the impact of COVID-19 pandemic on the care of underserved children with type 1 diabetes Role: Principal Investigator |
|
Texas Children's Hospital Pediatric Pilot Award (Tosur, Mustafa)Oct 1, 2019 - Sep 30, 2020 Texas Children's Hospital Dissection of heterogeneity of pediatric diabetes using islet autoimmunity and beta-cell function: A prospective pilot study Role Description: The goal of this study is to determine usefulness and validity of a novel classification of pediatric diabete. Role: Co-investigator |
|
R01DK121843 (REDONDO, MARIA JOSE)Aug 1, 2019 - Feb 28, 2025 NIH Type 1 Diabetes Genetic Risk Score in TrialNet Role: Study Principal Investigator |
|
Mike Hogg Foundation Award (Tosur, Mustafa)Jan 1, 2019 Mike Hogg Foundation Title: Identification of Novel Genetic Variants in Children with Maturity-Onset Diabetes of the Young by Whole Exome Sequencing Role Description: Goal: To identify novel genetic variants in children with “suspected” maturity-onset diabetes of the young but had negative genetic test results in clinicaly available commercial panel. Role: Co-investigator/mentor |
|
U54DK118638 (BALASUBRAMANYAM, ASHOK)Sep 10, 2018 - May 31, 2029 NIH RARE and Atypical Diabetes Network(RADIANT) Role Description: Goal: The purposes of this Center are to: foster the study of individuals with rare/atypical forms of diabetes mellitus; identify and analyze phenotypic and genotypic defects that may provide insights into more common, heterogeneous forms of Type 2 diabetes mellitus (T2DM) in the general population; and develop a community resource to advance research in this area through the collection and dissemination of data and samples for access by the broad research community. Role: Co-Investigator/Pediatric Site Principal Investigator |
|
BCM Precision Medicine and Population Health Award (Redondo, Maria J)Jun 1, 2018 - May 31, 2019 Baylor College of Medicine Precision Medicine in Pediatric Diabetes Role Description: The goal of this project is to apply to define clusters of phenotypically distinct types of pediatric diabetes in a multiethnic population of children with T1D and high prevalence of obesity. Role: Principal Investigator |
|
NIH 2 R01 DK112311-15A1 (Pietropaolo, Massimo T)Jul 1, 2017 - Jun 30, 2022 NIH NIDDK Enhancement of Biomarkers for Type 1 Diabetes Role Description: The goal of this study is to Utilize immunologic biomarkers, in particular a variant-specific IA-2 autoantibodies (IA-2var) incorporating amino acid residue variants (Cys27, Gly608 and Pro671) in the full length molecule, for prediction of T1D progression. Role: Co-Principal Investigator (MPI) |
|
CLBS03-P01 (Redondo, Maria J)Jul 1, 2017 - Jul 15, 2020 Caladrius A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal CD4+CD25+CD127lo/-FOXP3+ Regulatory T-cells [Tregs] in Adolescents with Recent Onset Type 1 Diabetes Mellitus. CLBS03-P01. Role Description: Goal: To evaluate the safety and efficacy of autologous ex vivo expanded T-Regulatory cells to preserve beta-cell function in youth with new onset type 1 diabetes. Role: Site Principal Investigator |
|
U01DK103180 (REDONDO, MARIA JOSE)Aug 1, 2014 - Apr 30, 2020 NIH Texas Children's Hospital and Baylor College of Medicine TrialNet Clinical Center Role: Principal Investigator |